Navigation Links
Lenalidomide prolongs disease control for multiple myeloma patients after stem cell transplant
Date:5/16/2012

PORTLAND, Ore. Multiple myeloma patients are better equipped to halt progression of this blood cancer if treated with lenalidomide, or Revlimid, following a stem cell transplant, according to a study co-authored by a physician with the Oregon Health & Science University Knight Cancer Institute.

The study, published in the New England Journal of Medicine, found a 63 percent reduction in the risk of progressive myeloma or death for the stem cell transplant patients that were treated with lenalidomide maintenance therapy.

"These results add to the evidence that the combination of standard therapies such as stem cell transplantation with the emerging biologic therapies, like lenalidomide, have extended the lives of multiple myeloma patients," said Richard Maziarz, M.D., of the OHSU Knight Cancer Institute who was one of the study's co-authors. Maziarz serves as medical director of the Adult Stem Cell Transplantation Program & Center for Hematologic Malignancies at the OHSU Knight Cancer Institute. "We know that for at least three years following a transplant that maintenance therapy with this drug vastly improves the chances that the cancer won't come back and worsen."

These data were supported by similar Phase III studies reported from France and Italy in the same issue of the New England Jounal of Medicine demonstrating that maintenance therapy after stem cell transplantation was associated with improved disease control.

Multiple myeloma is a cancer that affects plasma cells, a type of white blood cell normally responsible for producing antibodies. In patients impacted by multiple myeloma, collections of abnormal plasma cells accumulate in the bone marrow, interfering with the production of normal blood cells. The study focused on patients who received an autologous hematopoietic cell transplant (AHCT). AHCT procedures use patients' own blood stem cells.

While lenalidomide increased a patient's ability to stave off progression of the disease, questions remain regarding future approaches recognizing that quality of life measurements were not incorporated within these studies, that long-term safety issues remain unclear as there was a small but discernable risk of second cancers observed in the treated patients. In addition to the need for that cost-benefit analysis, a comparison remains to be performed with other emerging myeloma maintenance therapies.

This Phase III study of lenalidomide was conducted at 47 medical centers and involved 568 patients. It was sponsored by the National Cancer Institute (NCI). Revlimid's manufacturer, Celgene Corp., provided the NCI with lenalidomide for this research.


'/>"/>

Contact: Elisa Williams
willieli@ohsu.edu
503-494-4530
Oregon Health & Science University
Source:Eurekalert  

Related medicine news :

1. Study urges caution with lenalidomide dosage
2. How to recognize at an early stage whether a new cancer therapy prolongs life
3. Everolimus prolongs progression-free survival for patients with neuroendocrine tumors
4. Early life stress may predict cardiovascular disease
5. Study finds racial gaps continue in heart disease awareness
6. Bowel disease link to blood clots
7. Womens Heart Disease Awareness Still Lacking
8. American Heart Association Rapid Access Journal Report: Study Finds Racial Gaps Continue in Heart Disease Awareness, Low Knowledge of Heart Attack Warning Signs Among Women
9. New Study Uses Adult Stem Cells in Effort to Save Limbs of Patients with Peripheral Arterial Disease
10. Patients with Lethal Lung Disease Finally Receive Recognition by Social Security Administration
11. Alzheimers Foundation of America Applauds Social Security for Speeding Disability Benefits for Early-Onset Alzheimers Disease
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Lenalidomide prolongs disease control for multiple myeloma patients after stem cell transplant
(Date:3/28/2017)... ... 28, 2017 , ... For many women, getting birth control isn’t as easy as it should ... don’t have access to a health care facility or a pharmacy within 60 minutes of ... United States or for many who are faced with health or personal issues that leave ...
(Date:3/28/2017)... ... March 28, 2017 , ... Greenfield Advisors ... brings his extensive knowledge of appraisals, property values, ad valorem taxation, and government ... valuation industry for more than 40 years. , “Ruel is a great addition ...
(Date:3/28/2017)... ... March 28, 2017 , ... Revolution ... legislatures and Congress to protect parental rights and civil liberties, and to restore ... America. , The demonstration coincides with a press conference taking place Friday morning ...
(Date:3/28/2017)... ... 29, 2017 , ... Dr. Isabella Wentz, PharmD, FASCP, one of the leading ... The Thyroid Secret. Dr. Wentz talked about journey and research recently on a blog ... IS NOT the only solution to deal with thyroid disease. , Dr. Wentz ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... ... management software and services, is proud to announce it has joined the National ... association representing the interests of chronically ill, disabled, and dying Americans of all ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... -- The leader in accelerated orthodontics, OrthoAccel ® Technologies, ... Manal Ibrahim , Kenji Ojima , ... featured microlecture presenters at the AcceleDent ® booth ... Annual Session, April 21-25, 2017. Orthodontists and their staff ... 11:20 a.m. On the opening morning of AAO exhibitions, ...
(Date:3/29/2017)... , March 29, 2017  Maxor National Pharmacy Services, ... that it has named Leah Bailey as ... divisions of the company. With more than ... previous 8 years focused on health care, Bailey joins ... tenure at Prime, Bailey advised the PBM, Specialty, and ...
(Date:3/29/2017)... JOSE, Calif. , March 29, 2017  Designers ... now significantly reduce solution size by 50% and extend ... Q ) power management integrated circuit (PMIC) from Maxim ... wearable PMIC supports a low input voltage of just ... Zinc Air and Silver Oxide, as well as the ...
Breaking Medicine Technology: